

Kidney News

March 2013 | Vol. 5, Number 3

Innovation Center Announces Long-Awaited ESRD Care Model

By Rachel Shaffer



The government agency charged with developing new health care payment and service delivery models—CMS and its Center for Medicare and Medicaid Innovation (CMMI)—recently announced the Comprehensive ESRD Care Initiative.

The announcement marks the end of months of speculation about when—and whether—the Innovation Center would announce a coordinated care model for kidney care. ASN, along with many other stakeholders in the kidney community, advocated in support of such a model. However, as of press time, numerous details about the Innovation Center's vision for the program

remained unclear to many in the kidney community.

CMS began accepting letters of intent for the Comprehensive ESRD Care Initiative in early February. The Innovation Center states that it anticipates that 10 to 15 so-called ESRD Seamless Care Organizations (ESCOs) will participate in the model. The first performance period for the model will begin in the fourth quarter of 2013, and interested participants must submit a letter of intent by March 15 and apply by May 1.

Yet it is unclear how many dialysis organizations, nephrology providers, and other health professionals will ultimately participate—and whether CMS will consider altering specifics of the program.

The Comprehensive ESRD Care Initiative is the first chronic disease-specific shared savings model that the Innovation Center has launched. While other fields of medicine—in-

Continued on page 6

Inside

8 Journal View

Is daily dialysis linked to increased mortality?

11 Kidney News

interviews **NIDDK Director Griffin Rodgers** about the institute's priorities for research and funding.

13 Policy Update

Acute kidney injury is focus of World Kidney Day 2013, plus research and the Veterans Administration

14 Health Care Apps

Apps for diabetes care are ahead of those for kidney care. But do apps yield patient results?

17 Industry Spotlight

News in iron therapy and hyperphosphatemia treatment

Online Hemodiafiltration Prolongs Life Compared with Standard Hemodialysis

Results of Prospective Randomized Trial May Change Clinical Practice

Hemodialysis is now a routine renal replacement therapy with guaranteed short-term safety, but long-term outcomes are far from ideal. Retrospective studies suggest that online hemodiafiltration (OL-HDF) may reduce kidney failure patients' risk of premature death com-

pared with standard hemodialysis, but the results of prospective studies have failed to confirm this finding.

Hemodiafiltration differs from standard dialysis because it uses high convective transport to remove solutes over a wide range of sizes, including osteocalcin and beta2-microglobulin

(Maduell F, et al. *Am J Kidney Dis* 2002; 40(3):582–589).

New results from a multicenter, open-label, randomized controlled trial demonstrate the advantages of OL-HDF (Maduell F, et al. *J Am Soc Nephrol* 2013. doi: 10.1681/ASN.2012080875).

"In view of this study's results, OL-HDF may become the first-line option in hemodialysis patients," said first author Francisco Maduell, MD, PhD, of the Hospital Clinic in Barcelona, Spain.

Continued on page 2

Online Hemodiafiltration

Continued from page 1

ESHOL study

A total of 906 dialysis patients were assigned to either continue hemodialysis or switch to OL-HDF, with higher convective volume than in previous prospective trials. The patients were followed up for 3 years as part of the On-Line Hemodiafiltration Survival Study, or Estudio de Supervivencia de Hemodiafiltración On-Line (ESHOL).

Compared with patients who continued on hemodialysis, those assigned to OL-HDF had a 30 percent lower risk of dying of any cause, a 33 percent lower risk of dying of cardiovascular-related causes, and a 55 percent lower risk of dying of an infection. Also, hospitalizations and dialysis sessions complicated by low blood pressure were lower in patients assigned to OL-HDF.

“The reduction in all-cause mortality associated with OL-HDF treatment observed in this trial was focused on cardiovascular and infectious diseases. Cardiovascular disease is the most common cause of mortality in chronic hemodialysis patients, and the mortality rate is still 10 times higher than in the general population,” said Maduell. “Also, end stage renal disease patients have a significant risk of infectious complications, which represent the first cause of hospitalization and the second cause of death in hemodialysis patients.”

The risk reductions shown in the ESHOL study suggest that switching eight patients from hemodialysis to OL-HDF may prevent one annual death.

Differences from previous studies

Results of earlier studies on hemodiafiltration were disappointing.

Two recent prospective, randomized trials failed to demonstrate a survival advantage of OL-HDF over hemodialysis. In the Dutch Convective Transport (CONTRAST) study, 714 prevalent dialysis patients were randomized to low-flux hemodialysis or OL-HDF, with an average follow-up time of 3 years. No survival difference between the groups was observed at the end of the study, (Grooteman MPC, et al. *J Am Soc Nephrol* 2012; 23:1087–1096). In the Turkish Online Haemodiafiltration Study, 782 prevalent dialysis patients were randomized to high-flux hemodialysis or OL-HDF, and, again, all-cause mortality was not affected by treatment allocation during 2 years of follow-up (Ok E, et al. *Nephrol Dial Transplant* 2013; 28:192–202).

Convective volume seems to be an important issue, based on the results of the CONTRAST and Turkish studies, Maduell said.

“The studies showed a 39 percent and 46 percent mortality risk reduction in patients receiving high convective volumes of greater than 22 and 20 liters per session, respectively,” he said. “These results provide evidence of the need to deliver high convective volumes to reduce all-cause mortality. To achieve this goal, high blood flow rates and long dialysis times are required.”

In the ESHOL study, the average blood flow rate was higher than in the CONTRAST and Turkish studies, whereas the average length of dialysis


was longer than in the CONTRAST study and similar to that of the Turkish study. These factors led to a higher average delivered convective volume in the ESHOL study (23.7 L/session) than in the CONTRAST and Turkish studies (20.7 L).

“Our results indicate that the treatment modality could modify patient survival when a sufficient convective volume is reached,” said Maduell.

Others in the field agree. Richard Ward, PhD, a professor of medicine in the kidney disease program at the

University of Louisville, noted that the study is important for two main reasons: it is the first to show an unequivocal survival benefit from OL-HDF, and it confirms post-hoc analyses from the previous two studies, suggesting that the realization of a survival benefit requires the delivery of a minimum convective volume of about 24 L.

“My hope is that this article will provide the final push to see the introduction of online hemodiafiltration in the United States,” Ward said. “The three randomized trials published in



IN aHUS, TMA CAUSES COMPLEMENT-MEDIATED SUDDEN AND PROGRESSIVE ORGAN FAILURE AND PREMATURE DEATH¹⁻⁵

To learn more about aHUS, visit aHUSSource.com or call OneSource at 1.888.765.4747

References: 1. Loirat C, Garnier A, Sellier-Leclerc A-L, Kwon T. *Semin Thromb Hemost*. 2010;36:673–681. 2. Loirat C, Noris M, Frermeaux-Bacchi V. *Pediatr Nephrol*. 2008;23:1957–1972. 3. Noris M, Caprioli J, Breslin E, et al. *Clin J Am Soc Nephrol*. 2010;5:1844–1859. 4. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. *Br J Haematol*. 2008;143:336–348. 5. Sallée M, Daniel L, Piercecchi M-D, et al. *Nephrol Dial Transplant*. 2010;25:2028–2032. 6. Caprioli J, Noris M, Brioschi S, et al; for the International Registry of Recurrent and Familial HUS/TTP. *Blood*. 2006;108:1267–1279. 7. Ariceta G, Besbas N, Johnson S, et al; for the European Paediatric Study Group for HUS. *Pediatr Nephrol*. 2009;24:687–696.

the last 12 months, together with everyday clinical experience from use of the therapy in many other countries, show that online hemodiafiltration can be performed safely. Moreover, with the blood flow rates commonly used in the United States, it should not be difficult to deliver the convective volumes associated with reduced mortality.”

Enric Vilar, MD, PhD, of the department of renal medicine at Lister Hospital in England, also noted that the study provides valuable clinically relevant data. “This is an important


randomized control trial with a clear message for the dialysis community,” Vilar said. “The positive results confirm the findings from previous cohort studies and also the CONTRAST study, which demonstrated improved survival for the subgroup with high substitution volume hemodiafiltration.”

Despite the positive findings from this trial, Maduell stressed that hemodiafiltration is far from perfect. “The main limitation is the belief that the technique solves all problems of hemodialysis. Many other aspects need to be

addressed to improve overall survival in the dialysis population—for example, getting a good vascular access, avoiding volume overload, and reducing cardiovascular risks,” he said.

Still, the study’s results indicate that widespread use of OL-HDF could have a considerable impact on dialysis patients’ health and longevity. “Mortality remains very high in dialysis patients, ranging from 15 percent to 25 percent annually. Any reduction of this mortality would be an important achievement,” Maduell said. ●

atypical Hemolytic Uremic Syndrome (aHUS)
is a chronic, genetic, lifelong disease of systemic,
complement-mediated thrombotic microangiopathy (TMA)
with catastrophic consequences.¹⁻⁵



Modified from Caprioli et al, 2006. Data shows patients with CFH mutations.
CFH mutations = most common population.²

**Early and
chronic
intervention
is critical^{6,7}**

- 33% to 40% of patients die or progress to end-stage renal disease (ESRD) with the first clinical manifestation^{3,6}
- 65% of all patients die, require dialysis, or have permanent renal damage within the first year after diagnosis despite plasma exchange or plasma infusion⁶

ALEXION

© 2012, Alexion Pharmaceuticals, Inc. All rights reserved. SOL-1270



**Maintain
your
certification
with ASN's**

Dialysis Practice Improvement Module

Available Now

ASN provides the best learning opportunities in kidney care. The Dialysis Practice Improvement Module (DPIM) guides physicians through a review of patient data and supports the implementation of a quality-improvement (QI) plan for their practice.

- Evaluate and improve care for dialysis patients
- Implement an individual or practice-wide improvement plan
- Earn 20 MOC points from ABIM

Online Learning | The ASN Advantage
www.asn-online.org/pim





KidneyNews

Editorial Staff

Editor-in-Chief: Pascale H. Lane, MD, FASN

Executive Editor: Dawn McCoy

Production and Content Editor: Kurtis Pivert

Design: Lisa Cain

Editorial Board:

Matthew D. Breyer, MD, FASN, Eli Lilly and Company

Wendy Weinstock Brown, MD, Jesse Brown VA Medical Center, Northwestern University Feinberg School of Medicine, University of Illinois at Chicago

Teri Browne, PhD, MSW, University of South Carolina

Ira Davis, MD, Baxter Healthcare Corp.

Nishank Jain, MD MPH (fellow), University of Texas Southwestern Medical Center

Caroline Jennette Poulton, MSW, University of North Carolina Kidney Center

Richard Lafayette, MD, Stanford University Medical Center

Edgar V. Lerma, MD, FASN, University of Illinois – Chicago /Associates in Nephrology, SC

Teri J. Mauch, MD, FASN, University of Utah

Victoria F. Norwood, MD, FASN, University of Virginia

Matthew A. Sparks, MD, Duke University Hospital

Titte R. Srinivas, MD, Cleveland Clinic

Advertising Sales:

The Walchli Tauber Group

2225 Old Emmorton Road, Suite 201

Bel Air, MD 21015

443-252-0571 Mobile

443-512-8899 *115 Phone

christine.kenney@wt-group.com

ASN Council:

President: Bruce A. Molitoris, MD, FASN

President-elect: Sharon M. Moe, MD, FASN

Past-President: Ronald J. Falk, MD, FASN

Secretary-Treasurer: Donald E. Wesson, MD, FASN

Publications Committee Chair: Sharon M. Moe, MD, FASN

Councillors: Jonathan Himmelfarb, MD, FASN, Raymond C. Harris, MD, FASN,

Eleanor D. Lederer, MD, FASN, Mark D. Okusa, MD, FASN

Executive Director: Tod Ibrahim

Associate Director of Publishing: Robert Henkel

ASN Kidney News is published by the American Society of Nephrology
1510 H Street NW, Suite 800, Washington, DC 20005. Phone: 202-640-4660

www.asn-online.org

ASN Kidney News is the authoritative source for analysis of trends in medicine, industry, and policy affecting all practitioners in nephrology. The statements and opinions expressed in ASN Kidney News are solely those of the authors and not of the American Society of Nephrology (ASN) or the editorial policy of the editors. The appearance of advertisements in ASN Kidney News is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The American Society of Nephrology disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

The American Society of Nephrology is organized and operated exclusively for scientific and educational purposes, including enhancing the field of nephrology by advancing the scientific knowledge and clinical practice of that discipline through stimulation of basic and clinical investigation, providing access to new knowledge through the publication of journals and the holding of scientific meetings, advocating for the development of national health policies to improve the quality of care for renal patients, cooperating with other national and international societies and organizations involved in the field of nephrology, and using other means as directed by the Council of the Society.

Postmaster: Please send address changes to ASN Kidney News, c/o Customer Service, American Society of Nephrology 1510 H Street NW, Suite 800, Washington, DC 20005.

Publications mail agreement No. 40624074. Return undeliverable Canadian addresses to PO Box 503, RPO West Beaver Creek, Richmond Hill ON L4B 4R6

ASN Kidney News (ISSN print 1943-8044 and online 1943-8052) is an official publication of the American Society of Nephrology, 1510 H Street NW #800, Washington DC 20005, and is published monthly. Periodicals postage paid at Washington, DC and at additional mailing offices. Subscription rates: \$12 per year. To order, please email bhenkel@asn-online.org. Subscription prices subject to change. Annual ASN membership dues include \$12 for ASN Kidney News subscription.

Copyright© 2013 All rights reserved



Corporate Supporters

ASN gratefully acknowledges the Society's Diamond and Platinum Corporate Supporters for their contributions in 2012.

Diamond Level

abbvie

AMGEN®

FRESENIUS
MEDICAL CARE

Otsuka
Otsuka America Pharmaceutical, Inc.

QUESTCOR®
PHARMACEUTICALS, INC.

REATA
PHARMACEUTICALS


SANOFI

Platinum Level

AFFYMAX®

Takeda

ALEXION



HeRO Graft bypasses central venous stenosis



HeRO (Hemodialysis Reliable OutFlow) Graft is the **ONLY** fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with **central venous stenosis**.

- **Fewer Infections:** 69% reduced infection rate compared with catheters¹
- **Superior Dialysis Adequacy:** 1.7 Kt/V, a 16% to 32% improvement compared with catheters¹
- **High Patency Rates:** Up to 87% cumulative patency at 2 years^{1, 2}
- **Cost Savings:** A 23% average savings per year compared with catheters³



Reducing Catheter Dependency

HeRO Graft Candidates

- Catheter-dependent or approaching catheter-dependency
- Failing AVF or AVG due to central venous stenosis

Treatment Algorithm

Failing AVF or AVG due to **central venous stenosis**



Catheter-dependent patients

Learn more at www.herograft.com

Order at: **888.427.9654**

References:

1) Katzman et al., J Vasc Surg 2009. 2) Gage et al., EJVES 2012. 3) Dageforde et al., JSR 2012.

Indications for Use: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. See Instructions for Use for full indication, contraindication and caution statements. Rx only.

HeRO Graft is classified by the FDA as a vascular graft prosthesis.

1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • Phone (888) 427-9654 • (770) 419-3355

All trademarks are owned by CryoLife, Inc. or its subsidiaries. HeRO Graft is a Hemosphere, Inc. product distributed by CryoLife, Inc. and Hemosphere, Inc. © 2012 CryoLife, Inc. All rights reserved.



1. Download the App
2. Scan the code with your mobile device to watch video

Get the free mobile app at
<http://gettag.mobi>

 **CryoLife**[®]
Life Restoring Technologies[®]

mend other considerations for optimal implementation of ESCOs.

Another aspect of the RFA that has raised some concern in the community is the minimum 500 patient threshold for an ESCO. Given CMS' stipulation that the area that an ESCO defines may be no larger than two contiguous Medicare core-based statistical areas, it may be hard for some smaller—and even potentially some larger—dialysis organizations to meet that threshold. Related to the threshold concern is the fact that beneficiaries who have already

been matched to a Medicare ACO or another Medicare program/demonstration/model involving shared savings at the date of initial matching for the ESCO program are ineligible for the ESCO. In markets with one large ACO or multiple ACOs, the possibility that patients have already matched and are ineligible is a real possibility.

As more clarity around the RFA and more news of the community's reaction unfolds, look for additional coverage and analysis of ESCOs in *ASN Kidney News*. ●

Table 1

CMS priorities for determining quality measures

- Appropriate to the health issues of dialysis patients
- Effective for quality of care monitoring and program oversight
- Inclusive of process and outcome measures that will enable a robust evaluation of patient-provider and delivery system outcomes
- Conducive to use across clinical methods, modalities, and care settings
- Effective for incentivizing better care, better health, and lower costs across Medicare Part A, Part B, Part D, and Medicaid programs
- Inclusive of measures for appropriate medication utilization
- Straightforward to operationalize and measure
- Inclusive of other CMS ESRD quality initiative data

Important Safety Information: (cont)

- *myfortic* is contraindicated in patients with hypersensitivity to mycophenolate sodium, mycophenolic acid (MPA), mycophenolate mofetil (MMF), or to any of its excipients
- *Embryofetal Toxicity:* *myfortic* can cause fetal harm when administered to a pregnant female. Use of *myfortic* during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations
- *Pregnancy Exposure Prevention and Planning:* FRP must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations, and must be counseled regarding pregnancy prevention and planning. (See additional important Pregnancy Testing, Contraception, and Pregnancy Planning information below)
- *Lymphoma and Other Malignancies:* Patients receiving immunosuppressive regimens involving combinations of drugs, including *myfortic*, as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin
- *Infections:* Oversuppression of the immune system can also increase susceptibility to infection, fatal infections, and sepsis
- *Polyomavirus Infections:* Immunosuppressed patients are at increased risk for opportunistic infections, including Polyomavirus infections. Polyomavirus infections in transplant patients may have serious and sometimes fatal outcomes. These include cases of JC virus-associated progressive multifocal leukoencephalopathy (PML) and Polyomavirus-associated nephropathy (PVAN), especially due to BK virus infections, which have been observed in patients receiving *myfortic*. PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal graft loss. Patient monitoring may help detect patients at risk for PVAN
- Cases of PML have been reported in patients treated with MPA derivatives including MMF and mycophenolate sodium. PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms, and consultation with a neurologist should be considered as clinically indicated. Reduction in immunosuppression should be considered for patients who develop evidence of PML or PVAN. Physicians should also consider the risk that reduced immunosuppression represents to the graft
- *Blood Dyscrasias Including Pure Red Cell Aplasia:* Cases of pure red cell aplasia (PRCA) have been reported in patients treated with MPA in combination with other immunosuppressive agents. In some cases, PRCA was found to be reversible with dose reduction or cessation of therapy with MPA derivatives. In transplant patients, however, reduced immunosuppression may place the graft at risk. Patients receiving *myfortic* should be monitored for blood dyscrasias (eg, neutropenia or anemia). If blood dyscrasias occur (eg, neutropenia develops [ANC <1.3 x 10³/μL or anemia]), dosing with *myfortic* should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately
- *Pregnancy Testing:* To prevent unplanned exposure during pregnancy, FRP should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting *myfortic*. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient. In the event of a positive pregnancy test, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations
- *Contraception:* FRP taking *myfortic* must receive contraceptive counseling and use acceptable contraception during the entire *myfortic* therapy, and for 6 weeks after stopping *myfortic*, unless the patient chooses abstinence. Patients should be aware that *myfortic* reduces blood levels of the hormones in the oral contraceptive pill, and could theoretically reduce its effectiveness. (Please see package insert for acceptable contraceptive methods for females)
- *Pregnancy Planning:* For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of *myfortic* should be discussed with the patient
- *Gastrointestinal Disorders:* Gastrointestinal bleeding (requiring hospitalization) has been reported in *de novo* renal transplant patients (1.0%) and maintenance patients (1.3%) treated with *myfortic* (up to 12 months)
- *Patients with Renal Impairment:* Subjects with severe chronic renal impairment (GFR <25 mL/min/1.73 m²) may present higher plasma MPA and MPAG AUC relative to subjects with lesser degrees of renal impairment or normal healthy volunteers. No data are available on the safety of long-term exposure to these levels of MPAG
- *Concomitant Medications:* Caution should be used with drugs that interfere with enterohepatic recirculation because of the potential to reduce efficacy
- *Hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) Deficiency:* *myfortic* should be avoided in patients with HGPRT deficiency such as Lesch-Nyhan and Kelley-Seegmiller syndrome
- *Immunizations:* Use of live attenuated vaccines should be avoided
- The principal adverse reactions associated with the administration of *myfortic* include constipation, nausea, and urinary tract infection in *de novo* patients and nausea, diarrhea, and nasopharyngitis in maintenance patients

References: 1. FDA/Center for Drug Evaluation and Research. FDA approved drug products: mycophenolate mofetil. Drugs@FDA Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_drug_name. Updated January 13, 2012. Accessed January 13, 2012. 2. Data on file. IMS Health, National Prescription Audit TRx Data: December 2011 to November 2012.

Please see Brief Summary of Prescribing Information, including **Boxed WARNINGS**, on adjacent pages.



Journal View

Daily Dialysis Linked to Increased Mortality

Patients receiving daily in-center dialysis have a higher risk of death than those receiving conventional three-times-weekly dialysis, according to a report in *Kidney International*. Using an international registry, the researchers identified 556 patients in France, the United States, and Canada who received daily hemodialysis (more than five times weekly) between 2001 and 2010. Propensity

score techniques were used to match 318 patients receiving daily hemodialysis with 575 patients receiving conventional hemodialysis (three times weekly) during the same period. Mortality on the two dialysis schedules was compared by Cox proportional hazards. The daily hemodialysis group received dialysis nearly twice as often as the conventional group: mean 5.8 sessions per week.

The mean weekly dialysis times were 15.7 hours versus 11.9 hours, respectively. There were 170 deaths over 1382 patient-years of follow-up. The mortality was substantially higher for patients receiving daily hemodialysis: 15.6 versus 10.9 deaths per 100 person-years, hazard ratio 1.6. The results were similar in matched and unmatched adjusted analyses and in specified

subgroup analyses. There was also evidence that daily hemodialysis was poorly tolerated—30 percent of patients switched to conventional hemodialysis after a median of 10 months. Previous reports have suggested improvement in health-related quality of life and other outcomes for patients undergoing daily hemodialysis. This cohort study, how-

**Myfortic®
(mycophenolic acid*)
delayed-release tablets
*as mycophenolate sodium**

Rx only

BRIEF SUMMARY: Please see package insert for full prescribing information.

WARNING

EMBRYOFETAL TOXICITY, MALIGNANCIES AND SERIOUS INFECTIONS

Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning. (see WARNINGS and PRECAUTIONS)

Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma and other neoplasms. Only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should use Myfortic® (mycophenolic acid). Patients receiving Myfortic should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow up of the patient. (see WARNINGS and PRECAUTIONS)

INDICATIONS AND USAGE
Myfortic® (mycophenolic acid) delayed-release tablets are indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

CONTRAINDICATIONS
Myfortic® (mycophenolic acid) is contraindicated in patients with a hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or to any of its excipients.

WARNINGS (SEE BOXED WARNING)
EMBRYOFETAL TOXICITY
Myfortic can cause fetal harm when administered to a pregnant female. Use of Myfortic during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidney (see **PRECAUTIONS: Pregnancy**).

Pregnancy Exposure Prevention and Planning
Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning. For recommended pregnancy testing and contraception methods (see **PRECAUTIONS: Pregnancy Exposure Prevention and Planning**).

Lymphoma and Other Malignancies
Patients receiving immunosuppressive regimens involving combinations of drugs, including Myfortic® (mycophenolic acid), as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see **ADVERSE REACTIONS**). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.

The rates for lymphoproliferative disease or lymphoma in Myfortic-treated patients were comparable to the mycophenolate mofetil group in the *de novo* and maintenance studies (see **ADVERSE REACTIONS**). As usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.

Infections
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections, fatal infections, and sepsis. Fatal infections can occur in patients receiving immunosuppressive therapy (see **ADVERSE REACTIONS**).

Polyomavirus Infections
Patients receiving immunosuppressants, including Myfortic are at increased risk for opportunistic infections, including Polyomavirus infections. Polyomavirus infections in transplant patients may have serious, and sometimes, fatal outcomes. These include cases of JC virus associated progressive multifocal leukoencephalopathy (PML) and Polyomavirus associated nephropathy (PVAN) especially due to BK virus infection which have been observed in patients receiving Myfortic.

PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal graft loss (see **ADVERSE REACTIONS**). Patient monitoring may help detect patients at risk for PVAN.

Cases of PML, have been reported in patients treated with MPA derivatives which include mycophenolate mofetil (MMF) and mycophenolate sodium (see **ADVERSE REACTIONS**). PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies and ataxia. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated.

Reduction in immunosuppression should be considered for patients who develop evidence of PML or PVAN. Physicians should also consider the risk that reduced immunosuppression represents to the functioning allograft.

Blood Dyscrasias Including Pure Red Cell Aplasia
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolic acid (MPA) derivatives in combination with other immunosuppressive agents. The mechanism for MPA derivatives induced PRCA is unknown; the relative contribution of other immunosuppressants and their combinations in an immunosuppressive regimen is also unknown. In some cases PRCA was found to be reversible with dose reduction or cessation of therapy with MPA derivatives. In transplant patients, however, reduced immunosuppression may place the graft at risk. Changes to Myfortic therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimize the risk of graft rejection (see **ADVERSE REACTIONS, Post-marketing Experience**).

Patients receiving Myfortic should be monitored for blood dyscrasias (e.g. neutropenia or anemia (see **PRECAUTIONS, Laboratory Tests**). The development of neutropenia may be related to Myfortic itself, concomitant medications, viral infections, or some combination of these events. If blood dyscrasias occur (e.g. neutropenia (ANC <1.3x10³/µL or anemia)), dosing with Myfortic should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately (see **DOSAGE AND ADMINISTRATION in the full prescribing information**).

Patients receiving Myfortic should be instructed to immediately report any evidence of infection, unexpected bruising, bleeding, or any other manifestation of bone marrow suppression.

Concomitant Use
Myfortic has been administered in combination with the following agents in clinical trials: antithymocyte/lymphocyte immunoglobulin, muromonab-CD3, basiliximab, daclizumab, cyclosporine, and corticosteroids. The efficacy and safety of Myfortic in combination with other immunosuppression agents have not been determined.

PRECAUTIONS
Pregnancy Exposure Prevention and Planning
Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.

Females of reproductive potential include girls who have entered puberty and all women who have a uterus and have not passed through menopause. Menopause is the permanent end of menstruation and fertility. Menopause should be clinically confirmed by a patient's healthcare practitioner. Some commonly used diagnostic criteria include 1) 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or 2) post-surgical from a bilateral oophorectomy.

Pregnancy Testing
To prevent unplanned exposure during pregnancy, females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting Myfortic. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient.

In the event of a positive pregnancy test, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations.

Contraception
Females of reproductive potential taking Myfortic must receive contraceptive counseling and use acceptable contraception (see **Table 4 for Acceptable Contraception Methods**). Patients must use acceptable birth control during entire Myfortic therapy, and for 6 weeks after stopping Myfortic, unless the patient chooses abstinence (she chooses to avoid heterosexual intercourse completely).

Patients should be aware that Myfortic reduces blood levels of the hormones in the oral contraceptive pill and could theoretically reduce its effectiveness (see **PRECAUTIONS: Information for Patients** and **PRECAUTIONS: Drug Interactions: Oral Contraceptives**).

Table 4 Acceptable Contraception Methods for Females of Reproductive Potential

Pick from the following birth control options:			
Option 1			
Methods to Use Alone	Intrauterine devices (IUDs) Tubal sterilization Patient's partner had a vasectomy		
OR			
Option 2	Hormone Methods choose 1		Barrier Methods choose 1
Choose One Hormone Method AND One Barrier Method	Estrogen and Progestosterone Oral Contraceptive Pill Transdermal patch Vaginal ring	AND	Diaphragm with spermicide Cervical cap with spermicide Contraceptive sponge Male condom Female condom
	Progestosterone-only Injection Implant		
OR			
Option 3	Barrier Methods choose 1		Barrier Methods choose 1
Choose One Barrier Method from each column (<i>must choose two methods</i>)	Diaphragm with spermicide Cervical cap with spermicide Contraceptive sponge	AND	Male condom Female condom

Pregnancy Planning
For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of Myfortic should be discussed with the patient.

Gastrointestinal Disorders
Gastrointestinal bleeding (requiring hospitalization) has been reported in *de novo* renal transplant patients (1.0%) and maintenance patients (1.3%) treated with Myfortic® (mycophenolic acid) (up to 12 months). Intestinal perforations, gastrointestinal hemorrhage, gastric ulcers and duodenal ulcers have rarely been observed. Most patients receiving Myfortic were also receiving other drugs known to be associated with these complications. Patients with active peptic ulcer disease were excluded from enrollment in studies with Myfortic. Because MPA derivatives have been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, hemorrhage, and perforation, Myfortic should be administered with caution in patients with active serious digestive system disease (see **ADVERSE REACTIONS**).

Patients with Renal Impairment
Subjects with severe chronic renal impairment (GFR <25 mL/min/1.73 m²) may present higher plasma MPA and MPAG AUCs relative to subjects with lesser degrees of renal impairment or normal healthy volunteers. No data are available on the safety of long-term exposure to these levels of MPAG.

In the *de novo* study, 18.3% of Myfortic patients versus 16.7% in the mycophenolate mofetil group experienced delayed graft function (DGF). Although patients with DGF experienced a higher incidence of certain adverse events (anemia, leukopenia, and hyperkalemia) than patients without DGF, these events in DGF patients were not more frequent in patients receiving Myfortic compared to mycophenolate mofetil. No dose adjustment is recommended for these patients; however, such patients should be carefully observed (see **CLINICAL PHARMACOLOGY AND DOSAGE AND ADMINISTRATION in the full prescribing information**).

Concomitant Medications
In view of the significant reduction in the AUC of MPA by cholestyramine when administered with mycophenolate mofetil, caution should be used in the concomitant administration of Myfortic with drugs that interfere with enterohepatic recirculation because of the potential to reduce the efficacy (see **PRECAUTIONS, Drug Interactions**).

ever, finds that mortality is actually higher for patients receiving daily hemodialysis compared with the conventional schedule. Although daily dialysis may have quality-of-life benefits, it cannot be recommended on the basis of improved survival [Suri RS, et al. A multinational cohort study of in-center daily hemodialysis and patient survival. *Kidney Int* 2013; 83:300–307]. ●

Conservative Kidney Management: Quantity and Quality of Life

For patients with advanced kidney failure, conservative kidney management (CKM) is associated with shorter survival compared with dialysis, with no decrease in quality of life, reports a study in the *Clinical Journal of the American Society of Nephrology*. The prospective study included 170 elderly patients with advanced, progressive chronic kidney disease: late stage 4 or stage

5. After standard assessments and discussions with patients and family members, 80 patients began to undergo (or were planned for) hemodialysis and 44 received peritoneal dialysis. Thirty patients opted for CKM, which consisted of ongoing medical treatment and multidisciplinary support. The remaining 16 patients remained undecided.

Patients underwent assessments of quality of life, anxiety and depression, and satisfaction with life for as long as 3 years. Quality of life and survival were compared among groups. Patients selecting CKM were older, had more dependency needs, and had more comorbidity. Patients in the CKM group

Continued on page 10

Myfortic® (mycophenolic acid*) delayed-release tablets *as mycophenolate sodium

Patients with HGPRT Deficiency
On theoretical grounds, because Myfortic is an IMPDH Inhibitor, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.

Immunizations
During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective (**see PRECAUTIONS, Drug Interactions, Live Vaccines**).

Laboratory Tests
Complete blood count should be performed weekly during the first month, twice monthly for the second and the third month of treatment, then monthly through the first year. If neutropenia develops (ANC <1.3×10⁹/μL), dosing with Myfortic should be interrupted or the dose reduced, appropriate tests performed, and the patient managed accordingly (**see WARNINGS**).

Drug Interactions
The following drug interaction studies have been conducted with Myfortic:

Gastroprotective agents
Antacids with magnesium and aluminum hydroxides:
Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum-containing antacids (30 mL): the mean C_{max} and AUC₍₀₋₁₎ values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. It is recommended that Myfortic and antacids not be administered simultaneously.

Proton Pump Inhibitors:
In a study conducted in 12 healthy volunteers, the pharmacokinetics of MPA were observed to be similar when a single dose of 720 mg Myfortic was administered alone and following concomitant administration of Myfortic and pantoprazole, which was administered at a dose of 40 mg BID for 4 days.

Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady-state dosing of Myfortic.

The following recommendations are derived from drug interaction studies conducted following the administration of mycophenolate mofetil:

Acyclovir/Ganciclovir: May be taken with Myfortic; however, during the period of treatment, physicians should monitor blood cell counts. Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.

Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.

Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.

Oral Contraceptives: In a drug-drug interaction study, mean levonorgestrel AUC was decreased by 15% when coadministered with mycophenolate mofetil. Although Myfortic may not have any influence on the ovulation-suppressing action of oral contraceptives, it is recommended to co-administer Myfortic with hormonal contraceptives, (e.g. birth control pill, transdermal patch, vaginal ring, injection, and implant) with caution and additional barrier contraceptive methods must be used. (**see PRECAUTIONS: Pregnancy Exposure Prevention and Planning**).

Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination (**see PRECAUTIONS, General**).

Drugs that alter the gastrointestinal flora may interact with Myfortic by disrupting enterohepatic recirculation. Interference of MPAG hydrolysis may lead to less MPA available for absorption.

Carcinogenesis, Mutagenesis, Impairment of Fertility
In a 104-week oral carcinogenicity study in rats, mycophenolate sodium was not tumorigenic at daily doses up to 9 mg/kg, the highest dose tested. This dose resulted in approximately 0.6-1.2 times the systemic exposure (based upon plasma AUC) observed in renal transplant patients at the recommended dose of 1.44 g/day. Similar results were observed in a parallel study in rats performed with mycophenolate mofetil. In a 104-week oral carcinogenicity study in mice, mycophenolate mofetil was not tumorigenic at a daily dose level as high as 180 mg/kg (which corresponds to 0.6 times the proposed mycophenolate sodium therapeutic dose based upon body surface area).

The genotoxic potential of mycophenolate sodium was determined in five assays. Mycophenolate sodium was genotoxic in the mouse lymphoma/thymidine kinase assay, the micronucleus test in V79 Chinese hamster cells, and the *in-vivo* mouse micronucleus assay. Mycophenolate sodium was not genotoxic in the bacterial mutation assay (*Salmonella typhimurium* TA 1535, 97a, 98, 100, & 102) or the chromosomal aberration assay in human lymphocytes. Mycophenolate mofetil generated similar genotoxic activity. The genotoxic activity of MPA is probably due to the depletion of the nucleotide pool required for DNA synthesis as a result of the pharmacodynamic mode of action of MPA (inhibition of nucleotide synthesis).

Mycophenolate sodium had no effect on male rat fertility at daily oral doses as high as 18 mg/kg and exhibited no testicular or spermatogenic effects at daily oral doses of 20 mg/kg for 13 weeks (approximately two-fold the therapeutic systemic exposure of MPA). No effects on female fertility were seen up to a daily dose of 20 mg/kg, which was approximately three-fold higher than the recommended therapeutic dose based upon systemic exposure.

Pregnancy
Pregnancy Category D (See WARNINGS)
Following oral or IV administration, MMF is metabolized to mycophenolic acid (MPA), the active ingredient in Myfortic and the active form of the drug. Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidney. In animal studies, congenital malformations and pregnancy loss occurred when pregnant rats and rabbits received mycophenolic acid at dose multiples similar to and less than clinical doses. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Risks and benefits of Myfortic should be discussed with the patient. When appropriate, consider alternative immunosuppressants with less potential for embryofetal toxicity. In certain situations, the patient and her healthcare practitioner may decide that the maternal benefits outweigh the risks to the fetus. For those females using Myfortic at any time during pregnancy and those becoming pregnant within 6 weeks of discontinuing therapy, the healthcare practitioner should report the pregnancy to the Mycophenolate Pregnancy Registry (1-800-617-8191). The healthcare practitioner should strongly encourage the patient to enroll in the pregnancy registry. The information provided to the registry will help the Health Care Community to better understand the effects of mycophenolate in pregnancy.

In the National Transplantation Pregnancy Registry (NTPR), there were data on 33 MMF-exposed pregnancies in 24 transplant patients; there were 15 spontaneous abortions (45%) and 18 live-born infants. Four of these 18 infants had structural malformations (22%). In postmarketing data (collected from 1995 to 2007) on 77 women exposed to systemic MMF during pregnancy, 25 had spontaneous abortions and 14 had a malformed infant or fetus. Six of 14 malformed offspring had ear abnormalities. Because these postmarketing data are reported voluntarily, it is not always possible to reliably estimate the frequency of particular adverse outcomes. These malformations are similar to findings in animal reproductive toxicology studies. For comparison, the background rate for congenital anomalies in the United States is about 3%, and NTPR data show a rate of 4-5% among babies born to organ transplant patients using other immunosuppressive drugs. There are no relevant qualitative or quantitative differences in the teratogenic potential of mycophenolate sodium and mycophenolate mofetil.

In a teratology study performed with mycophenolate sodium in rats, at a dose as low as 1 mg/kg, malformations in the offspring were observed, including anophthalmia, exencephaly and umbilical hernia. The systemic exposure at this dose represents 0.05 times the clinical exposure at the dose of 1.44 g/day Myfortic. In teratology studies in rabbits, fetal resorptions and malformations occurred from 80 mg/kg/day, in the absence of maternal toxicity (dose levels are equivalent to about 0.8 times the recommended clinical dose, corrected for BSA).

Nursing Mothers
It is not known whether MPA is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from MPA, a decision should be made whether to discontinue the drug or to discontinue nursing while on treatment or within 6 weeks after stopping therapy, taking into account the importance of the drug to the mother.

Pediatric Use
De novo Renal Transplant
The safety and effectiveness of Myfortic in *de novo* pediatric renal transplant patients have not been established.

Stable Renal Transplant
There are no pharmacokinetic data available for pediatric patients <5 years. The safety and effectiveness of Myfortic have been established in the age group 5-16 years in stable pediatric renal transplant patients. Use of Myfortic in this age group is supported by evidence from adequate and well-controlled studies of Myfortic in stable adult renal transplant patients. Limited pharmacokinetic data are available for stable pediatric renal transplant patients in the age group 5-16 years. Pediatric doses for patients with BSA <1.19 m² cannot be accurately administered using currently available formulations of Myfortic tablets (**see CLINICAL PHARMACOLOGY, Special Populations and DOSAGE AND ADMINISTRATION in the full prescribing information**).

Geriatric Use
Patients ≥65 years may generally be at increased risk of adverse drug reactions due to immuno-suppression. Clinical studies of Myfortic did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS
The incidence of adverse events for Myfortic® (mycophenolic acid) was determined in randomized, comparative, active-controlled, double-blind, double-dummy trials in prevention of acute rejection in *de novo* and maintenance kidney transplant patients.

The principal adverse reactions associated with the administration of Myfortic include constipation, nausea, and urinary tract infection in *de novo* patients and nausea, diarrhea and nasopharyngitis in maintenance patients.

Adverse events reported in ≥20% of patients receiving Myfortic or mycophenolate mofetil in the 12-month *de novo* renal study and maintenance renal study, when used in combination with cyclosporine, USP (MODIFIED) and corticosteroids, are listed in Table 5. Adverse event rates were similar between Myfortic and mycophenolate mofetil in both *de novo* and maintenance patients.

Table 5 Adverse Events (%) in Controlled de novo and Maintenance Renal Studies Reported in ≥20% of Patients

	<i>de novo</i> Renal Study Myfortic® 1.44 g/day (n=213)	mycophenolate mofetil 2 g/day (n=210)	Maintenance Renal Study Myfortic® 1.44 g/day (n=159)	mycophenolate mofetil 2 g/day (n=163)
Blood and Lymphatic System Disorders				
Anemia	21.6	21.9	—	—
Leukopenia	19.2	20.5	—	—
Gastrointestinal System Disorders				
Constipation	38.0	39.5	—	—
Nausea	29.1	27.1	24.5	19.0
Diarrhea	23.5	24.8	21.4	24.5
Vomiting	23.0	20.0	—	—
Dyspepsia	22.5	19.0	—	—
Infections and Infestations				
Urinary Tract Infection	29.1	33.3	—	—
CMV Infection	20.2	18.1	—	—
Nervous System Disorder				
Insomnia	23.5	23.8	—	—
Surgical and Medical Procedure				
Postoperative Pain	23.9	18.6	—	—

Journal View

Conservative Kidney Managment

Continued from page 9

also had poorer physical health and higher anxiety than did those choosing dialysis. Most quality-of-life measures showed no significant change over time, regardless of

treatment choice. The exception was life satisfaction, which decreased after the start of treatment in the dialysis groups but remained unchanged in the CKM group. Survival was shorter for patients choosing CKM, after comorbidity, performance status, age, physical health, and propensity score were controlled for. Patients in the dialysis groups survived a median of 1317 days after enrollment, compared with 913 days in the CKM group. Conservative kidney management may

be considered by elderly patients with advanced kidney failure, for whom the benefits of dialysis are questionable. This study shows that quality of life tends to be maintained in patients opting for CKM, compared with those starting dialysis. This must be weighed against substantially shorter survival with CKM. [Da Silva-Gane, et al. Quality of life and survival in patients with advanced kidney failure managed conservatively or by dialysis. *Clin J Am Soc Nephrol* 2012; 7:2002–2009]. ●

Hypertension Carries Higher Stroke Risk in Black Patients

At a given level of blood pressure, the risk of stroke associated with hypertension is higher for black than in white patients, according to a report in *JAMA Internal Medicine*.

The study included data on nearly 28,000 black and white participants 45 years and older in a population-based follow-up study of stroke risk factors. The study oversampled blacks and residents of the “stroke belt” of the southeastern United States. Proportional hazards models were used to assess differences in stroke risk factors and outcomes for black and white participants in three age groups (less than 65 years, 65 to 74 years, and 75 years and older) and three systolic blood pressure levels (less than 120 mm Hg, 120 to 139 mm Hg, and 140 to 159 mm Hg).

The analysis included 715 incident strokes over 4.5 years of follow-up. Black participants were more likely to be taking antihypertensive drugs. They also had higher rates of diabetes and left ventricular hypertrophy but lower rates of atrial fibrillation, smoking, and heart disease.

Per 10 mm Hg increase in systolic blood pressure, stroke risk increased by 24 percent for black participants versus 8 percent for white participants. This racial disparity was still significant after adjustment for other risk factors. The racial difference was greatest for participants 45 to 64 years. In this age group, the odds ratio for stroke among black participants was 1.38 for those with prehypertension and 2.38 for those with stage 1 hypertension. (For those with normal blood pressure, the racial difference was nonsignificant.)

The results show a greater increase in stroke risk associated with hypertension in black versus white patients, at similar ages and blood pressure levels. The authors note that black patients are more likely to have hypertension and less likely to have it under control, with uncontrolled blood pressure leading to a higher risk of incident stroke. Blood pressure may help to explain the recognized higher risk of stroke among black Americans, particularly during middle age [Howard G, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. *JAMA Intern Med* 2013; 173:46–51]. ●

Myfortic® (mycophenolic acid*) delayed-release tablets *as mycophenolate sodium

Table 6 summarizes the incidence of opportunistic infections in *de novo* and maintenance transplant patients, which were similar in both treatment groups.

Table 6 Viral and Fungal Infections (%) Reported Over 0-12 Months

	<i>de novo</i> Renal Study Myfortic® mycophenolate 1.44 g/day (n = 213)		Maintenance Renal Study Myfortic® mycophenolate 2 g/day (n = 159)	
	(%)	(%)	(%)	(%)
Any Cytomegalovirus	21.6	20.5	1.9	1.8
- Cytomegalovirus Disease	4.7	4.3	0	0.6
Herpes Simplex	8.0	6.2	1.3	2.5
Herpes Zoster	4.7	3.8	1.9	3.1
Any Fungal Infection	10.8	11.9	2.5	1.8
- Candida NOS	5.6	6.2	0	1.8
- Candida Albicans	2.3	3.8	0.6	0

The following opportunistic infections occurred rarely in the above controlled trials: aspergillus and cryptococcus.

The incidence of malignancies and lymphoma is consistent with that reported in the literature for this patient population. Lymphoma developed in 2 *de novo* patients (0.9%), (one diagnosed 9 days after treatment initiation) and in 2 maintenance patients (1.3%) (one was AIDS-related), receiving Myfortic with other immunosuppressive agents in the 12-month controlled clinical trials. Nonmelanoma skin carcinoma occurred in 0.9% *de novo* and 1.8% maintenance patients. Other types of malignancy occurred in 0.5% *de novo* and 0.6% maintenance patients.

The following adverse events were reported between 3% to <20% incidence in *de novo* and maintenance patients treated with Myfortic in combination with cyclosporine and corticosteroids are listed in Table 7.

Table 7 Adverse Events Reported in 3% to <20% of Patients Treated with Myfortic® in Combination with Cyclosporine* and Corticosteroids

	<i>de novo</i> Renal Study	Maintenance Renal Study
Blood and Lymphatic Disorders	Lymphocele, thrombocytopenia	Leukopenia, anemia
Cardiac Disorder	Tachycardia	–
Eye Disorder	Vision blurred	–
Endocrine Disorders	Cushingoid, hirsutism	–
Gastrointestinal Disorders	Abdominal pain upper, flatulence, abdominal distension, sore throat, abdominal pain lower, abdominal pain, gingival hyperplasia, loose stool	Vomiting, dyspepsia, abdominal pain, constipation, gastroesophageal reflux disease, loose stool, flatulence, abdominal pain upper
General Disorders and Administration Site Conditions	Edema, edema lower limb, pyrexia, pain, fatigue, edema peripheral, chest pain	Fatigue, pyrexia, edema, chest pain, peripheral edema
Infections and Infestations	Nasopharyngitis, herpes simplex, upper respiratory tract infection, oral candidiasis, herpes zoster, sinusitis, wound infection, implant infection, pneumonia	Nasopharyngitis, upper respiratory tract infection, urinary tract infection, influenza, sinusitis
Injury, Poisoning, and Procedural Complications	Drug toxicity	Postprocedural pain
Investigations	Blood creatinine increased, hemoglobin decrease, blood pressure increased, liver function tests abnormal	Blood creatinine increase, weight increase
Metabolism and Nutrition Disorders	Hypocalcemia, hyperuricemia, hyperlipidemia, hypokalemia, hypophosphatemia, hypercholesterolemia, hyperkalemia, hypomagnesemia, diabetes mellitus, hyperphosphatemia, dehydration, fluid overload, hyperglycemia, hypercalcemia	Dehydration, hypokalemia, hypercholesterolemia
Musculoskeletal and Connective Tissue Disorders	Back pain, arthralgia, pain in limb, muscle cramps, myalgia	Arthralgia, pain in limb, back pain, muscle cramps, peripheral swelling, myalgia
Nervous System Disorders	Tremor, headache, dizziness (excluding vertigo)	Headache, dizziness
Psychiatric Disorders	Anxiety	Insomnia, depression
Renal and Urinary Disorders	Renal tubular necrosis, renal impairment, dysuria, hematuria, hydronephrosis, bladder spasm, urinary retention	–
Respiratory, Thoracic and Mediastinal Disorders	Cough, dyspnea, dyspnea exertional	Cough, dyspnea, pharyngolaryngeal pain, sinus congestion
Skin and Subcutaneous Tissue Disorders	Acne, pruritus	Rash, contusion
Surgical and Medical Procedures	Complications of transplant surgery, postoperative complications, postoperative wound complication	–
Vascular Disorders	Hypertension, hypertension aggravated, hypotension	Hypertension

*USP (MODIFIED)

The following additional adverse reactions have been associated with the exposure to MPA when administered as a sodium salt or as mofetil ester:

Gastrointestinal: Colitis (sometimes caused by CMV), pancreatitis, esophagitis, intestinal perforation, gastrointestinal hemorrhage, gastric ulcers, duodenal ulcers, and ileus (**see PRECAUTIONS**).

Resistance Mechanism Disorders: Serious life-threatening infections such as meningitis and infectious endocarditis have been reported occasionally and there is evidence of a higher frequency of certain types of serious infections such as tuberculosis and atypical mycobacterial infection.

Respiratory: Interstitial lung disorders, including fatal pulmonary fibrosis, have been reported rarely with MPA administration and should be considered in the differential diagnosis of pulmonary symptoms ranging from dyspnea to respiratory failure in posttransplant patients receiving MPA derivatives.

Postmarketing Experience: The following adverse reactions have been identified during post-approval use of Myfortic. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.

Congenital disorder: Embryofetal toxicity: Congenital malformations and an increased incidence of first trimester pregnancy loss have been reported following exposure to mycophenolate mofetil (MMF) during pregnancy (**see PRECAUTIONS: Pregnancy**).

Infections: Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with MPA derivatives (**see WARNINGS, Polyomavirus Infections**). Polyomavirus associated nephropathy (PVAN), especially due to BK virus infection, has been observed in patients receiving immunosuppressants, including Myfortic. This infection is associated with serious outcomes, including deteriorating renal function and renal graft loss (**see WARNINGS, Polyomavirus Infections**).

Hematologic: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with MPA derivatives in combination with other immunosuppressive agents (**see WARNINGS**).

Dermatologic: Cases of rash have been reported in patients treated with MPA derivatives.

OVERDOSAGE

Signs and Symptoms
There has been no reported experience of acute overdose of Myfortic® (mycophenolic acid) in humans.

Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Treatment and Management

General supportive measures and symptomatic treatment should be followed in all cases of overdose. Although dialysis may be used to remove the inactive metabolite MPAG, it would not be expected to remove clinically significant amounts of the active moiety MPA due to the 98% plasma protein binding of MPA. By interfering with enterohepatic circulation of MPA, activated charcoal or bile acid sequestrants, such as cholestyramine, may reduce the systemic MPA exposure.

Storage
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture.

Dispense in a tight container (USP).

Handling
Tablets should not be crushed or cut.

Manufactured by:
Novartis Pharma Stein AG
Stein, Switzerland

Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

© Novartis

T2012-126
June 2012

NIDDK Director Speaks with ASN Kidney News



NIDDK Director Griffin Rodgers, MD

KN:

You have led the NIDDK for more than 6 years. Tell us about the institute and your vision of NIDDK's role in promoting scientific endeavor.

Rodgers:

As the NIDDK's director, I want to underscore the institute's commitment to vigorous, multipronged research efforts. In particular, I want to respond to two questions I have been asked at recent meetings with NIDDK constituency groups: "How will NIDDK research move forward now and in the future?" and "How will the institute meet the challenges of the current budget landscape?"

Clearly, at all levels of the NIDDK we will continue to pursue the most compelling research to combat the many debilitating and costly chronic diseases within our mission: kidney and urologic diseases, diabetes and other endocrine and metabolic diseases, liver and other digestive diseases, nutritional disorders, obesity, and hematologic diseases. Moreover, we will remain firmly committed to basic, translational, and clinical research; research training and career development; and the dissemination of health information to improve the lives of patients, their families, and those at risk for these diseases.

Together, we at NIDDK will build upon the emerging opportunities that are the fruits of past research investments. Through careful planning and analysis, we will meet the challenge of deploying our budgetary resources in the most effective and efficient ways to sustain research momentum and fully capitalize on research achievements. In moving research forward, several overarching principles will guide my leadership and that of the NIDDK extramural division directors:

- **Maintaining a vigorous investigator-initiated research portfolio.** The innovations and problem-solving skills of individual investigators are crucial for research progress. Therefore, NIDDK will maintain funding of investigator-initiated grants at the highest possible level. We will also maximize our investments by supporting cross-cutting science that is broadly applicable to many

disease-specific research issues. Examples include identification of biomarkers that can aid in disease diagnosis and assessment of new treatments in clinical trials, development of cell-based therapeutic approaches for repairing damaged tissues, and the use of cutting-edge research methods to identify new candidate drugs.

- **Supporting pivotal clinical studies and trials.** Clinical studies will continue to be an integral component of research on the broad spectrum of diseases for which NIDDK has research responsibility. We have supported large epidemiologic studies of chronic kidney disease (CKD) in adults through the Chronic Renal Insufficiency Cohort (CRIC), and in children through the Chronic Kidney Disease in Children Prospective Cohort (CKiD). Shortly, NIDDK will fund new clinical studies and trial initiatives in glomerular diseases, CKD, and end stage renal disease (ESRD). Because many of these diseases disproportionately affect minority populations, we will continue to seek insights and answers to health disparities. For example, we will continue to ensure substantial minority participation in clinical trials relevant to these diseases. We are also maximizing our investments by expanding the investigative community's access to the valuable research resources accrued in our major clinical trials. We are doing this by funding ancillary studies to these trials and by supporting a central repository for biologic materials from clinical trials.

them with our entire community.

- **Ensuring knowledge dissemination through outreach and communications.** We are continuing efforts to ensure that the science-based knowledge gained from NIDDK-funded research is imparted to health care providers and the public for the direct benefit of patients and their families. Examples include the National Kidney Disease Education Program (NKDEP), the National Diabetes Education Program (NDEP), the Weight-control Information Network (WIN), and new programs to promote celiac disease awareness and the prevention of obesity in children.

As we plan for the future, we will continue to seek and value external advice from investigators, professional scientific organizations, patient advocates, and the public. Key sources of input will continue to be our National Advisory Council, Interagency Coordinating Committees, strategic planning processes like the Kidney Research National Dialogue (KRND), ad hoc planning groups, and scientific conferences and workshops. This input will provide a useful scientific guidepost as we make resource allocation decisions. Active collaboration with other components of the NIH and other federal agencies will also remain a cornerstone of NIDDK planning efforts

Ever-increasing knowledge and the advent of new technologies bring new scientific opportunities for alleviating and conquering the many chronic diseases within the NIDDK's mission. Our continuing

Together, we at NIDDK will build upon the emerging opportunities that are the fruits of past research investments. Through careful planning and analysis, we will meet the challenge of deploying our budgetary resources in the most effective and efficient ways to sustain research momentum and fully capitalize on research achievements.

—Griffin Rodgers

- **Preserving a stable pool of talented new investigators.** The ideas and fresh perspectives of new investigators invigorate the research community. We will strive to ensure that today's generation of young scientists can realize their potential for contributing to biomedical research and will view research as a viable career. We will foster mentorship through our K Awardee (career development) workshops and New PI workshops for first-time RO1 investigators, and promote special consideration for funding of talented new investigators through the use of differential paylines and special emphasis.
- **Fostering exceptional research training and mentoring opportunities.** Maintaining an NIDDK-focused pipeline of outstanding investigators is critically important to our research progress. We will continue to support significant opportunities at the graduate and postdoctoral levels, as well as through research career development awards and undergraduate research educational opportunities. To ensure that we are deploying our research training resources most productively, we are analyzing data to determine the most effective aspects of training programs so that we can share

goal will be to seize and maximize these opportunities to reduce the burden of disease and improve the public health. To this end, I look forward to working with the NIDDK's many stakeholders now and in the future.

KN:

What are the most important things you take into account when allocating funds, and how much discretion do NIH and NIDDK have in allocating research dollars?

Rodgers:

A substantial percentage of budget allocation is dedicated to investigator-initiated grants, in accordance with the available NIDDK payline. The proportion that goes to kidney disease thus depends on the number of applications and how well they score in review. The institute also has a process for larger (more costly) initiatives, although this has become smaller with the flattening of the NIH budget. Initiatives are proposed by KUH (kidney, urologic, and hematologic diseases) program staff and are then

Continued on page 12

NIDDK

Continued from page 11

reviewed for scientific opportunity by the NIDDK Council. Finally, kidney investigator-initiated applications have competed successfully for Common Fund, T1D, and large-scale genetics projects. Topics include “Kidney on a Chip,” “Metabolomics in CKD,” “Systems Biology Approaches for Diabetic Nephropathy,” a cluster randomized trial in patients on dialysis that is part of an NIH health systems collaborative, and a clinical trial to determine the value of APOL1 screening.

KN:

NIDDK spearheaded the Kidney Research National Dialogue (KRND). How has the information NIDDK gathered altered the planned Blueprint for Kidney Research?

Rodgers:

NIDDK has completed the first phase of KRND and is working on the development of the individual chapters for the “Blueprint for Kidney Research,” which also will be published as a series of individual commentaries in the *Clinical Journal of the American Society of Nephrology (CJASN)*. Responses to the question, “What are the critical questions and objectives in kidney research?”—which numbered over 270—were broad ranging and insightful. Upon review, the collection of questions in a particular kidney research area captured the distinctiveness of each field’s critical questions. However, it has become clear that more discussions are needed to refine the content of the individual topic discussions to truly capture the current state of each field and provide high-impact conceptual models, recommendations, and potential “roadmaps.” These second-level discussions are now being completed through a hybrid structure of electronic discourse and telephone conferencing. We have taken postings from the KRND and the individual chapter commentaries into consideration during the development of current initiatives.

KN:

What will the KRND mean to individual investigators?

Rodgers:

The KRND is a good source of ideas for trainees, early stage investigators, and seasoned, established investigators who wish to think more deeply about their own research trajectory. We hope it will stimulate innovative directions that advance kidney research and aid in establishing research collaborations. Our hope is that the *CJASN* commentaries will effectively communicate these ideas to the broadest community possible.

KN:

Has the focus on translational research at NIH changed funding goals at individual institutes?

Rodgers:

NIDDK’s research portfolio supports a broad range of science, including patient-oriented clinical research, basic and translational research, clinical trials,

pragmatic clinical trials, public health, and translation to the clinic. Translational research serves as an evolving source for new ideas and thoughtful future directions, but is only one part of the portfolio.

KN:

What do you consider the most promising translational opportunities in kidney research and practice?

Rodgers:

The most promising translational opportunities at the moment are those that pertain to glomerular disease, CKD, dialysis, and acute kidney injury (AKI). We have put forth recent funding announcements in all of these areas. We also encourage investigators and associated small start-up companies working on innovative devices, tools, and drugs to submit Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applications, as congressionally mandated funding has increased in these areas.

KN:

The percentage of funded grant applications is decreasing, and automatic spending cuts may take effect between 2013 and 2021. If automatic spending cuts go into effect, how should investigators and research institutions prepare?

Rodgers:

This is quite difficult to predict, yet it goes without saying that the high quality of research must be maintained in the face of any future spending cuts. We are attempting to support all five of our core principles as strongly as possible during periods of fiscal uncertainty.

KN:

How does NIDDK balance approaches to retain established researchers with the need to attract new researchers to the field?

Rodgers:

The NIDDK tries very hard to do both, largely through a special emphasis on funding and bridge awards for established investigators who just missed the payline, and via concerted efforts to entice undergraduate, medical school, and doctoral students to consider nephrology as a research career. We also give a special advantage to early stage investigators with a differential payline, as well as particular consideration of those who just missed the payline. We have recently hosted a mentoring workshop for our first-time R01 investigators (New PI Workshop) and are actively planning a similar one for our career development awardees (K Awardee Workshop). Finally, we just set up a Facebook page for our training and career programs (<http://www.facebook.com/NIDDKKUHtrainee>). We need to attract new researchers’ talent and ideas to sustain nephrology research in the future.

KN:

Many scientists and clinicians struggle to help resolve disparities in kidney disease. What are

the most important recent gains in this area?

Rodgers:

There have been gains in the identification of genetic markers for risk of glomerular disease and CKD in African Americans, but significant disparities remain in outcomes. The rate of CKD in African Americans is not greater than the rate for whites, but the rate of ESRD is much higher for African Americans. I think the new genetic findings hold potential promise, but we still do not know how to operationalize them. This is an active area of investigation that may provide clinical benefits. Perhaps this will help resolve a paradoxical finding in the ESRD literature that showed despite decreased access to care and increased socioeconomic challenges, African American hemodialysis patients survive longer than white patients—an unresolved mystery that if solved could provide public health insights. The NKDEP program has been very active in finding ways to get the message out to minority communities and others with increased risk of CKD and to the providers who serve them.

KN:

In 2007 the NIDDK wrote about the economic imperative to conquer diabetes. Doesn’t the same kind of imperative exist for kidney disease?

Rodgers:

It absolutely does. The NIDDK supports a wide range of studies:

- Basic science, including physiology, pathophysiology, development, injury, repair, and regeneration
- Epidemiology research, such as the aforementioned CRIC and CKiD studies, and the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI)
- Translational research, including the Diabetic Complications Consortium (DCC) and the CKD Biomarker Consortium
- Clinical trials, including new RFAs in 2013 for glomerular, CKD, and ESRD clinical study initiatives

KN:

What do you consider the greatest opportunity for kidney researchers over the next decade? Could antifibrotic research not only point toward better management of kidney disease, but lead to actual regression? If so, how?

Rodgers:

I believe that over the next 10 years, we will see significant strides in the treatment of fibrosis, whether the fibrosis is a result of glomerular disease, slowly progressive CKD, or follows a bout of AKI. Recent research in animal models has pointed to many potential targets to limit, if not reverse progressive fibrosis in the kidney and other organs. We are designing a future initiative that has a long-term aim to find agents that reverse established disease—through repair, regeneration, or reversal of fibrosis. ●

Policy Update

World Kidney Day 2013 Highlights Acute Kidney Injury

By Sarah Faubel, MD; Stuart Goldstein; and Bertrand Jaber on behalf of the ASN Acute Kidney Injury Advisory Group

Acute kidney injury (AKI) is a serious and growing public health problem that is encountered in the hospital setting. AKI is associated with a higher short-term risk of in-hospital death, and AKI-associated costs have been estimated at \$10 billion annually in the United States, due in part to extended hospital length of stays and use of renal replacement therapies. Survivors of episodes of AKI remain at increased risk of development and progression of chronic kidney disease, end stage kidney failure, and death. Unfortunately, at present, there exist no specific therapies aimed at preventing or treating AKI and its associated complications with the exception of supportive care, including renal replacement therapies.

Launched in 2006, World Kidney Day broadcasts an annual message about kidney disease to the public, government health officials, and health care providers, including general practitioners. Over the past seven years, this effort has focused on early detection of kidney disease, kidney protection measures, and kidney organ donation. This year, World Kidney Day—March 14, 2013—focuses on AKI to raise awareness and promote discussion, education, and policy development with the hope of improving prevention and treatment of this condition.

The AKI Advisory Group is leading ASN's efforts to commemorate the day. In preparation for World Kidney Day 2013, the AKI Advisory Group conducted a large systematic review and meta-analysis aimed at estimating the worldwide incidence of AKI and its stages of severity and associated mortality. The review also aims to describe geographic variations according to countries, regions, and their economies. The advisory group also completed a narrative review on the importance of transitions of care following hospital episodes of AKI calling for studies aimed at identifying patients at risk for developing chronic kidney disease and in need of targeted interventions. To further raise awareness of AKI, on World Kidney Day, the AKI Advisory Group will conduct a survey of nephrologists to determine the number of cases of AKI seen in the United States on one particular day. This survey may help assess the burden of AKI as a function of the overall practice of nephrology (see more below).

The epidemiology of AKI has undergone a dramatic shift in the past two decades. Medical providers increasingly understand that AKI is independently associated with poor patient outcomes. The major clinical contexts

studied have included those in which the timing of AKI is known and predictable (e.g., cardiopulmonary bypass) or when mortality is very high, such as in patients admitted to the intensive care unit with septic shock.

Numerous studies such as RIFLE and AKIN, as well as improved criteria for assessing AKI (KDIGO) have demonstrated that AKI may manifest as a secondary syndrome associated with another system illness and/or its treatment. Recently, increased attention has focused on nephrotoxic agents used for diagnostic purposes, including iodinated contrast agents required for imaging studies, as well as the multiple nephrotoxins prescribed to treat underlying illness or symptoms, which range from non-steroidal inflammatory drugs, antimicrobials, to chemotherapeutic agents.

Recent data show that over 80 percent of hospitalized patients are exposed to at least one nephrotoxic medication. Nephrotoxic medication-associated AKI is often non-oliguric, so clinicians should monitor kidney func-

On World Kidney Day 2013 ASN will conduct a survey of its U.S. members to provide a snapshot of AKI on this one day. Participants will be asked to keep track of the number of patients with AKI they see in the hospital relative to the total number of cases seen.

tion closely in the at-risk patient receiving a nephrotoxin. Given the increased evidence that AKI can lead to CKD, increased awareness of AKI risks and outcomes by non-nephrologists, and their collaboration with nephrologists, can improve outcomes.

As understanding of the epidemiology of AKI has emerged, so too has the importance of characterizing the public health burden of AKI, particularly in regard to its daily impact. Therefore, on World Kidney Day 2013 ASN will conduct a survey of its U.S. members to provide a snapshot of AKI on this one day. Participants will be asked to keep track of the number of patients with AKI they see in the hospital relative to the total number of cases seen.



Although much is known about the epidemiology of AKI, virtually nothing is known about the burden of AKI from a nephrologist's practice perspective. A picture of a "day in the life of AKI" will include an estimate of the number of cases of AKI, the number requiring renal replacement therapy, and the amount of in-hospital nephrology practice devoted to the care of patients with AKI.

All U.S. nephrologists are encouraged to participate, whether or not they see patients on World Kidney Day, as questions regarding overall practice related to AKI will also be asked. The information obtained in this survey will further raise awareness of AKI and its impact on public health. In summary, AKI continues to present a formidable challenge to health care providers and patients, and requires innovation in the prevention and treatment of this condition. With the launch of its new 2013 campaign, the AKI Advisory Group hopes to galvanize health care professionals and policy makers, in close collaboration with the public, to design better and safer health care delivery systems that focus on preserving kidney health through prevention and early detection and treatment of AKI, with the goal of mitigating the long-term costly burden of chronic kidney disease. ●

Sarah Faubel, MD, is affiliated with the Division of Nephrology, University of Colorado and Denver Veterans Administration Medical Center. Stuart Goldstein, MD, is affiliated with the Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center. Bertrand Jaber, MD, FASN, is affiliated with the Department of Medicine, Division of Nephrology, Kidney and Dialysis Research Laboratory, St. Elizabeth's Medical Center, Boston, and the Department of Medicine, Tufts University School of Medicine.

Paving the Way for Veterans' Health: A VA Research Primer

By Grant Olan

With a budget of \$1.95 billion last year, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the largest source of federal funding for kidney research, but certainly not the only one. The U.S. Department of Veterans Affairs (VA) has a comprehensive research portfolio aimed at advancing the treatment of kidney failure, as well as preventing and slowing the progression of kidney disease.

Like the National Institutes of Health (NIH), VA research grant proposals are subject to a peer review process. Only the most promising proposals based on

objective, evidence-based science are funded. Unlike NIH, the VA does not have an extramural research program. Consequently, all VA-funded investigators must hold a VA appointment such that at least five-eighths of their work time is with the agency.

Last year the VA released a report on "The State of VA Research" that highlights some significant kidney-related research, including a 2011 study that found cystatin C (a blood marker of kidney function) is significantly more accurate than the standard blood marker (creatinine) in predicting serious complications of kidney disease. "Among adults who were identified

as having kidney disease by high creatinine levels, the researchers found that only patients who also had abnormally high levels of cystatin C were at high risk for death, cardiovascular disease, heart failure, or kidney failure. People with high creatinine but normal cystatin C levels had risks similar to those with normal creatinine levels."

VA researchers also demonstrated in a large 2008 multisite clinical trial that more intensive treatment for acute kidney injury (the rapid loss of kidney function over a few hours or a few days)—e.g., dialysis six times

Continued on page 14

Policy Update

VA Research Primer

Continued from page 13

instead of three times per week—may not result in any added benefit.

One of ASN's top policy priorities is advancing support for medical research within federal research agencies, including the VA. ASN is on the Executive Committee of the Friends of VA Medical Care and Health Research (FOVA), and works closely with a number of other medical research advocacy coalitions.

FOVA was founded more than 20 years ago to ensure that America's veterans receive high-quality health care. Today, FOVA is a diverse coalition representing national academic, medical, and scientific societies; voluntary health and patient advocacy groups; and veteran-focused associations. FOVA works in concert with "The Independent Budget." The Independent Budget is a recommendation released annually by veterans' service organizations around the same time the President releases his annual budget recommendations. The recommendation is highly regarded and used by Congress to determine VA budget needs.

This year FOVA and The Independent Budget are recommending a \$611 million increase for the VA's Medical and Prosthetic Research account in Fiscal Year

2014, a \$30 million, or 5.2 percent, increase over 2012 levels. FOVA estimates that \$17 million, or 2.9 percent, of that total is needed to keep pace with the rising cost of medical research. The additional \$13 million is needed to support new research into conditions veterans returning from Iraq and Afghanistan face, including polytrauma, or multiple traumatic injuries such as a serious head injury in addition to a serious burn.

Thanks in part to the work of FOVA, the VA released a congressionally requested report last year detailing an in-depth survey and analysis of the physical condition of all VA research facilities (www.aamc.org/varpt). The survey and analysis evaluated and documented deficiencies in five areas and prioritized those deficiencies from 1 (life-threatening issues such as a chemical shower over electrical cords) to 5 (items that should be fixed but pose no threat to the health and safety of personnel are not required immediately). Altogether, the deficiencies total \$774 million to correct.

In response to this report, for the first time, FOVA and The Independent Budget are also making specific budget requests for VA research construction and infrastructure needs. Construction and infrastructure funding for VA research needs currently competes with funding for VA clinical needs like patient beds and elevators, which typically take precedence. As a conse-

quence, many VA facilities have run out of adequate research space, or existing space is unable to meet current research standards and safety codes.

FOVA believes specifically designating funds as a line item in the VA's budget to address these deficiencies is the only way to break this stalemate. Consequently, as a down payment for the \$774 million cost to correct all the deficiencies, FOVA is recommending \$50 million or more in Fiscal Year 2014 for up to five major VA research facility construction projects and \$175 million in non-recurring maintenance and minor construction funding to address priority 1 and 2 deficiencies identified in the 2012 VA research facility report.

"VA research has led to countless discoveries and innovations that have advanced health care not just for our nation's veterans, but for all Americans. Now the architecture that made this possible is languishing, and in some cases literally falling apart around the investigators that work in VA research facilities," said John R. Sedor, MD, ASN Research Advocacy chair. "If we don't make the necessary investments to bring these facilities up to current code and standards, the VA will have a tough time attracting new investigators, and research will suffer as a consequence. ASN supports the important work that FOVA is doing to advance the VA research program." ●

Do Health Apps Yield Patient Results?

By Pascale Lane

"There's an app for that."

It seems like everything can now be managed from a smartphone. Apps abound to help us shop and work and play. Pets can even be fitted with GPS collars so we can track their travels over the Internet. More than 20,000 apps also claim to manage our health, including the most popular diet method in a *Consumer Reports* annual survey. Some may be revolutionary, while others may be useless.

Diet diaries and pedometers have made way for devices that chart workouts using GPS and accelerometers to directly measure activity. Other services let participants earn workout rewards or log miles for charities. Wi-fi chipped blood pressure cuffs and bathroom scales can send data straight to an online logbook, showing the health results of those efforts in the gym and kitchen.

On the provider side, apps make it easier to get up-to-the-minute data to help with diagnosis and treatment. Accessing the latest treatment guidelines just requires pulling out a smartphone and tapping its screen. Integration of electronic records into mobile devices helps us keep track of what is going on

with our patients, rather than relying on our (faulty) memories for after-hours calls. Choosing these sorts of apps requires little thought; they are clearly useful.

Things get trickier for patients. How can they know which apps provide useful health management, as opposed to others that may provide bad advice? Dedicated patient groups, the e-patients, may test and review apps for each other. At least one health app boutique service, Happtique (www.happtique.com), gathers apps for member review. Providers can use the platform to prescribe apps to their patients, even creating their own virtual app store. The platform also provides a secure environment for transmitting data from services such as glucose trackers to health care records.

Diabetes tracking may be the most advanced health app area. Glucose monitors and insulin pumps can send their data directly to online information hubs. Add in diet and activity tracking, and these services become a way to look at all aspects of glycemic control and effect over time.

What is missing for apps? Results. While these apps should provide patients better health support,

we do not have data to show better outcomes yet.

We also do not have the comprehensive apps for kidney patients that we do for diabetes. Where is the app that charts blood pressure, diet, and activity? Where is the diet tracker that can tell the user phosphate and potassium content of their food choices? Where is the dialysis tracker with blood pressure, weight, and dialysis settings automatically charted to look for trends?

Managing chronic disease means keeping track of all aspects of an illness. Treatment includes medications and diet, as well as monitoring signs and symptoms. Apps may help patients do this better, perhaps improving health outcomes. That is our goal, and there will be an app. ●

Pascale Lane, MD, is editor-in-chief of ASN Kidney News.



Something to Say?

ASN Kidney News accepts correspondence in response to published articles. Please submit all correspondence to kidneynews@asn-online.org





Time out.

Let's take a moment to look at the current state of the lab industry.

These days, a lot of labs are stripping away all of their value-added services and support to bring you that “unbelievably low” price. **At Spectra we believe the best price is one that doesn't come at a sacrifice to the quality of your results, efficiency of your staff, or the care of your patients.** We offer everything for one fair price—customer service, education and training, couriers, and medically necessary testing with no arbitrary limitations.

We're proud to have maintained our core business values to provide all the resources that are in the best interest of your staff and your patients.

www.spectra-labs.com





Face the boards with confidence

ASN Board Review Course & Update 2013

**Registration
Opens
Friday, March 1**

August 10 – August 16
Chicago Marriott Downtown
Chicago, IL

Visit www.asn-online.org/brcu for more information

Industry Spotlight

Amgen Fourth Quarter Profits Drop, Revenue Up for 2012

Amgen finished 2012 with lower fourth-quarter profits—reporting a net income of \$788 million—despite an 11 percent increase in revenue for the quarter to \$4.42 billion. Increased spending on research and development and other administrative costs led to the 16 percent decline for the quarter compared to 2011.

For 2012, revenues at the biotechnology company also rose 11 percent for the year, totaling \$17.3 billion. This performance also reflects the costs of Amgen's acquisition of deCODE Genetics—a biotechnology company based in Iceland that focuses on identifying genetic risk factors for disease development—which was finalized in December of last year.

Amgen's anemia drugs contributed to the weak fourth-quarter performance, with Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) sales falling by 9 percent and 1 percent, respectively. For 2012, Aranesp and Epogen sales declined 11 percent and 5 percent, respectively,

driven by changing practice patterns and reduced dosing. Introduction of new drugs to treat anemia in patients receiving dialysis could lead to a more competitive environment for this therapeutic area, and possibly pose additional challenges to sales.

Demand for other medications in Amgen's nephrology portfolio remained strong. Sales of Sensipar (cinacalcet), a treatment for secondary hyperparathyroidism, were up 19 percent in the fourth quarter of 2012 and 18 percent for the year.

Looking ahead to 2013, Amgen's chairman and CEO Robert A. Bradway announced several new phase III trials, including one for AMG 145 for individuals with high LDL cholesterol levels. "We enter 2013 with good momentum, a broad late-stage pipeline, and a continued focus on building our business internationally," he said. However, the company announced plans in January to lay off 160 employees, or 1 percent of its workforce. ●

New Hyperphosphatemia Treatment Meets Phase III End Points

Keryx Biopharmaceuticals recently announced that the phase III clinical trial of its drug Zerenex (ferric citrate) successfully met its predetermined end points. Conducted under a Special Protocol Agreement, the study assessed the oral ferric iron-based compound for the treatment of hyperphosphatemia in patients with ESRD who are receiving dialysis.

The multicenter, randomized, open-label trial involved 441 patients with ESRD who were undergoing either hemodialysis or peritoneal dialysis. The study was conducted in two stages, a 52-week safety assessment phase and a 4-week efficacy assessment phase, preceded by a 2-week washout interval.

Zerenex met the primary end point of significantly reducing serum phosphorus levels compared to placebo in the efficacy assessment phase. The drug also met all secondary end points during the 52-week safety assessment, including maintenance of serum phosphorus in the normal range (with a noninferiority comparison with Renvela [sevelamer carbonate]), increasing

ferritin and transferrin saturation levels, and reducing intravenous iron and erythropoiesis-stimulating agent use compared with the active control.

Based in New York City, Keryx also reported plans to file a New Drug Application for Zerenex with the Food and Drug Administration (FDA) and a Marketing Authorization Application with the European Medicines Agency in the second quarter of 2013.

The results of this trial follow the January 2013 announcement that Zerenex was submitted for approval in Japan by Japanese Tobacco, the company that sublicenses the drug from Keryx.

Current therapies for the treatment of hyperphosphatemia include Renvela and Renagel (sevelamer hydrochloride), both of which are manufactured by Sanofi.

Keryx has also initiated phase II development of Zerenex for the management of phosphorus and iron deficiency in patients with stage III–V CKD who are not receiving dialysis. ●

Canadian Biotech Merger Puts Focus on Nephrology Drugs

Two Canadian biotechnology firms—the publicly traded Isotechnika Pharma and privately held Aurinia Pharmaceuticals—will combine forces to concentrate on the nephrology therapeutic market. The companies will join together under the Aurinia banner to focus on developing the calcineurin inhibitor voclosporin, an immunosuppressant, for approval.

Although the merger is based in Canada, the deal has international overtones. If approved, the South Korean ILJIN Life Science—which owns the rights to voclosporin—will take a 25 percent ownership stake in the new Aurinia.

Vifor Pharma, the Swiss pharmaceutical company held by the Galenica Group, is also involved. In 2012 it signed a development and commercialization agreement with Isotechnika to market voclosporin for treatment of lupus and all proteinuric nephrology indications in the United States and other countries outside of Canada.

Aurinia itself was spun out from Vifor as a separate entity after the Swiss firm acquired Aspreva in 2008, a company that specialized in immunosuppressive thera-

pies, investigated lupus nephritis treatments, and conducted the Aspreva Lupus Management Study (ALMS).

Previously, voclosporin has been studied in the treatment of chronic noninfectious uveitis. However, the drug was withdrawn from approval for this indication in Europe because of a failure to demonstrate that its benefits outweighed its risks.

Isotechnika recently completed a phase IIb study of voclosporin for use in solid organ transplantation that demonstrated equivalence to tacrolimus in prevention of acute rejection.

"While there have been a number of advances in the treatment of lupus nephritis, there is no question that significant unmet medical need remains," said Neil Solomons, MD, the new company's chief medical officer. "To that end, we expect to launch this phase IIB study of voclosporin in lupus nephritis in 2013," he added.

Based in Edmonton, Alberta, Canada, Isotechnika anticipates completion of the deal by the end of the first quarter of 2013, pending shareholder and regulatory approval. ●

New Iron Therapy Successful in Reducing ESA Dosing

A novel iron supplement therapy under development at Rockwell Medical significantly reduced erythropoietin-stimulating agent (ESA) dosing by 37 percent over the course of a recent 9-month study. A randomized placebo-controlled phase II clinical trial demonstrated that the drug—soluble ferric pyrophosphate (SFP)—met the primary end point of lowering ESA use in patients with end stage renal disease (ESRD) receiving hemodialysis.

Unlike other iron supplement therapies, which are given intravenously, SFP is mixed into dialysate and administered during dialysis. SFP's unique mechanism simulates the body's delivery of dietary iron, which could contribute to its efficacy. Upon entering the bloodstream, the drug quickly binds to apotransferrin and travels to bone marrow.

The phase II PRIME trial involved 108 patients with ESRD receiving hemodialysis randomized to receive dialysate either with or without SFP. Hemoglobin levels in both the SFP and placebo groups were similar at the beginning and end of the trial. However, the ESA dosing needed

to maintain hemoglobin levels was significantly lower in the SFP group. In addition, SFP maintained iron balance without increasing iron stores in other organs and had a safety profile similar to placebo.

"We believe that SFP's unique ability to treat iron deficiency while dramatically reducing the need for ESA, without increasing iron stores, strengthens SFP's potential to become the market leading iron therapy treatment for CKD-HD patients," said Rockwell Medical President and CEO Robert Chioini. "SFP's ability to substantially reduce ESA use in the treatment of anemia should translate into significant cost savings in dialysis care while potentially lowering the serious risks associated with the dosing of ESAs."

Based in Michigan, Rockwell Medical is currently conducting a phase III trial of SFP for use in the treatment of anemia in patients with ESRD who are receiving hemodialysis. At the trial's conclusion, the company anticipates filing a new drug application with the U.S. Food and Drug Administration by the end of 2013. ●

Abbott Laboratories Spins Off AbbVie, Reports Dip in Fourth-Quarter Profits

Abbott Laboratories announced a 35 percent decrease in profits in the fourth quarter of 2012. Despite an increase in sales of more than 4 percent, net earnings for the quarter were \$1.05 billion, down from \$1.62 billion in 2011.

Early repayment of debt and costs associated with spinning off Abbott's biopharmaceutical business into a new company called AbbVie contributed to the drop at

the end of the last quarter. Finalized at the beginning of 2013, the new multinational will concentrate solely on the development of pharmaceuticals to treat complex diseases that affect broad patient populations.

The *Wall Street Journal's* Market Watch recently reported that Abbott's move to spin off AbbVie was "a bid for a higher market valuation for Abbott Labs' diversified businesses, which are poised for stronger earn-

ings growth in coming years than AbbVie."

Abbott will maintain its stable of diagnostic and endovascular devices, as well as diabetes, vision, and nutritional products.

AbbVie's focus is on drug development in therapeutic areas such as hepatitis C, rheumatoid arthritis, and multiple sclerosis. The new pharmaceutical firm also inherited several products from Abbott's nephrology portfolio, including Calcijex (calcitriol in-

jection) and Zemplar (paricalcitol).

"In 2012, we achieved a significant milestone in Abbott's 125-year history with the creation of AbbVie while delivering another year of strong results," Abbott's chairman and CEO Miles White said. "Abbott's mix of diversified health care businesses and pipeline is favorably aligned with key health care and emerging market trends and well positioned to deliver top-tier growth in 2013." ●

Classifieds

Kidney News Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses.

Display Advertising Rates

Ad Size	1x	3x
Full Page	\$2,450	\$2,275
1/2 Page	\$1,615	\$1,440
1/3 Page	\$1,395	\$1,335
1/4 Page	\$1,170	\$1,060
1/6 Page	\$1,005	\$ 995

Line Advertising Rates

Please contact for rate information

Closing Date & Cancellations:

Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

ALL ADS
MUST BE PREPAID

Contact:
Rhonda Beamer
rhonda.beamer@wt-group.com
P: 443-512-8899 x. 106 F: 443-512-8909

Nephrologist—Outpatient Director

The University of Colorado, Division of Renal Diseases and Hypertension is seeking a new faculty member at the Assistant or Associate Professor level with Board Certification in Nephrology to serve in the role of Director of Outpatient Services. Applicants should have a strong interest in a clinical educator position with special a focus on leadership in outpatient nephrology and outpatient dialysis. The candidate should have the desire and drive to grow and improve the existing outpatient program at the University of Colorado. Applicants should have three years or greater experience in a faculty position. Contact Brittney.Kuntz@ucdenver.edu.

CLASSIFIED ADVERTISING WORKS!


contact Rhonda Beamer
rhonda.beamer@wt-group.com
443-512-8899 x. 106

Now available
as a free
download from
the App Store.



Index to Advertisers

Alexion	Pages 2–3
Cryolife.	Page 5
Falcon	Back Page
Novartis	Pages 6–10
Spectra	Page 15



CJASN for iOS and Android

Access the latest research and commentary published in the Clinical Journal of the American Society of Nephrology from anywhere in the world.



Download these and other ASN apps at www.asn-online.org/media.





Turn your dialysis rounds into incentive payments.

Falcon EHR's integration of real-time dialysis data can help you document encounters more completely and efficiently for Meaningful Use.

Sign with Falcon EHR by May 1 and we will implement your practice in time to demonstrate Meaningful Use for 90 days in 2013.

LOCK IN YOUR IMPLEMENTATION SPOT TODAY TO AVOID MISSING THE NEXT CMS INCENTIVE DEADLINE.



1-877-99-FALCON | FalconEHR.com